Last reviewed · How we verify

NCT06801327: FISIOBRONCHI

Comparison Between Conventional Respiratory Physiotherapy and the Simeox Device in Patients With Bronchiectasis

Recruiting now NA Last updated 2 March 2026
What this trial tests

NA trial testing Simeox in Bronchiectasis Adult in 40 participants. Currently enrolling.

Timeline
1 December 2024
Primary endpoint
1 September 2026
1 December 2026

Quick facts

Lead sponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposesupportive care
Enrollment40
Start date1 December 2024
Primary completion1 September 2026
Estimated completion1 December 2026
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →

Who can join

18 and older, any sex, with Bronchiectasis Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Physiotherapy is a key treatment for patients with bronchiectasis. An evaluation of the parameters indicative of respiratory health in patients treated with two different respiratory physiotherapy techniques (conventional versus Simeox®) would be very useful in choosing physiotherapy treatments for bronchiectasis patients. A systematic review of the literature shows that there are no published studies evaluating the effectiveness of respiratory physiotherapy by analyzing the variation in resistance measured using the forced oscillation technique (FOT) in patients with bronchiectasis. The results of this study would add to those that have examined different physiotherapy techniques and could therefore contribute to the choice of the most appropriate technique for this category of patients. The trial is being conducted to answer the question: "How do respiratory parameters vary during treatment with two different respiratory physiotherapy techniques: conventional respiratory physiotherapy or that performed using the Simeox device?" Secondary objectives include the measurement of various functional parameters, such as vital signs (heart rate, respiratory rate, blood oxygenation, blood pressure values) and spirometry values (FEV1, FVC, TLC). The onset of adverse events, the degree of patient tolerance and relief, and respiratory health will also be assessed through the administration of various questionnaires commonly used in clinical practice. Additionally, changes in the quantity of sputum produced will be measured.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Simeox

Trials testing the same drug.

Other recruiting trials for Bronchiectasis Adult

Currently open trials in the same condition.

Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06801327.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing